• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • EA Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • EA Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Stay Updated
  • We’re hiring!

Kainomyx — Antimalarial Drug (2019)

  • Portfolio Area: Human Health and Wellbeing
  • Focus Area: Scientific Research
  • Organization Name: Kainomyx
  • Amount: $1,999,999

  • Award Date: May 2020

Table of Contents


    Grant investigators: Chris Somerville and Heather Youngs

    This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.


    Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.

    This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

    Related Items

    • Human Health and Wellbeing

      Stanford University — Research on Science and Innovation (Heidi Williams)

      Open Philanthropy recommended a grant of $600,823 to Stanford University to support a one-year period of research leave for Professor Heidi Williams. During this time, Professor Williams will pursue research...

      Read more
    • Human Health and Wellbeing

      University of Connecticut Health Center — Syphilis Vaccine Development

      Open Philanthropy recommended a grant of $4,563,250 to the University of Connecticut Health Center to support work by Kelly Hawley and Melissa Caimano on the development of a...

      Read more
    • Human Health and Wellbeing

      University of Washington — Syphilis Vaccine Development (David Baker and Neil King)

      Open Philanthropy recommended a grant of $283,539 to the University of Washington to support research by David Baker and Neil King aimed at developing a vaccine for syphilis....

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    Mailing Address
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    Sign Up to Follow Our Work

    Join Our Mailing List

    © Open Philanthropy 2022